Candidate: CINVANTI® (aprepitant)

Type: Substance P/neurokinin-1 (NK1) receptor antagonist, approved by the FDA and indicated in adults, in combination with other antiemetic agents, for various categories of nausea and vomiting associated with highly emetogenic cancer chemotherapy and moderately emetogenic cancer chemotherapy

Status: Heron on July 14 disclosed on Clinicaltrials.gov that it will launch the Phase I GUARDS-1 trial (NCT04470622) of CINVANTI in July. The randomized, double-blind, placebo-controlled study is designed to evaluate aprepitant injectable emulsion in early hospitalized adult patients with COVID-19. The study’s primary endpoint is the proportion of subjects alive and discharged from the hospital.

The trial is expected to enroll 100 participants, and have a primary completion date of September 2020.


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA